Brainstorm Cell Therapeutics (BCLI) Secures $16M Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn in ALS
Tweet Send to a Friend
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE